Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease
Metrics: PDF 787 views | HTML 1410 views | ?
Davide Franceschini1, Fiorenza De Rose1, Antonella Fogliata1, Piera Navarria1, Anna Maria Ascolese1, Ciro Franzese1, Tiziana Comito1, Angelo Tozzi1, Cristina Iftode1, Lucia Di Brina1, Giuseppe D’Agostino1, Elena Clerici1, Luca Cozzi1,2, Marta Scorsetti1,2
1Humanitas Cancer Center and Research Hospital, Radiosurgery and Radiotherapy Department, 20089 Milan-Rozzano, Italy
2Department of Biomedical Sciences, Humanitas University, 20089 Milan-Rozzano, Italy
Antonella Fogliata, email: firstname.lastname@example.org
Keywords: mediastinal nodes, SBRT, oligometastases
Received: March 21, 2016 Accepted: June 30, 2016 Published: July 24, 2016
Purpose: To evaluate the outcome of Stereotactic Body Radiation Therapy (SBRT) with Volumetric Modulated Arc Therapy (VMAT) for thoracic node metastases.
Results: 18 out of 29 patients presented with isolated thoracic node metastases with no other sites of disease. Median prescribed dose was 45Gy (range 30–60Gy).
Acute toxicity was recorded as G0 in 28 patients, while one patient was scored as G1. Late toxicity was G0 in 26 patients, one patient was scored G1, one as G2, and one as G4 presented acute myocardial infarction.
During follow up, the best local response was complete remission in 14 patients and partial remission in 11 patients. With a median follow up of 12 months (range 2–35) 9 patients died from disease progression, 10 were still alive with distant metastases, 5 had a locally controlled disease and 5 patients were disease free.
The median OS estimated was 18 months (76%, 49% at one, two years). The median PFS was 9 months (28%, 17% at one, two years).
Materials and Methods: Twenty-nine patients with 32 thoracic nodes metastases were treated with SBRT in our institution. Toxicities and response were assessed. Overall Survival (OS) and Progression Free Survival (PFS) were evaluated.
Conclusions: SBRT is an efficient treatment for thoracic node metastases.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.